AR075516A1 - Composicion farmaceutica para inhalacion - Google Patents
Composicion farmaceutica para inhalacionInfo
- Publication number
- AR075516A1 AR075516A1 ARP100100474A ARP100100474A AR075516A1 AR 075516 A1 AR075516 A1 AR 075516A1 AR P100100474 A ARP100100474 A AR P100100474A AR P100100474 A ARP100100474 A AR P100100474A AR 075516 A1 AR075516 A1 AR 075516A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhalation
- excipients
- lactose
- premixes
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composicion farmacéutica para inhalacion. Método para establecer las características de desempeno de dicha composicion y uso de dicha composicion en el tratamiento del asma, de la EPOC, de las alergias, de las enfermedades infecciosas y de las enfermedades del sistema cardiovascular. Reivindicacion 1: Un método para establecer las características de desempeno de una composicion farmacéutica para inhalacion, caracterizado porque comprende los siguientes pasos: a) proveer al menos dos premezclas, cada una de las cuales contiene una mezcla de un ingrediente con actividad farmacéutica y un excipiente apropiado; b) mezclar las al menos dos premezclas; y c) introducir la mezcla en un dispositivo de administracion apropiado, capaz de administrar la fraccion de medicamento en el sistema pulmonar de un paciente, donde la relacion de peso entre los excipientes de las al menos dos premezclas se fija entre 1 y 5. Reivindicacion 2: El método de la reivindicacion 1, caracterizado porque los excipientes usados en las distintas premezclas son iguales o diferentes. Reivindicacion 3: El método de la reivindicacion 2, caracterizado porque los excipientes son diferentes desde el punto de vista químico. Reivindicacion 4: El método de la reivindicacion 2 o 3, caracterizado porque el valor d50 de los excipientes individuales difiere más de 10%, preferiblemente más de 15%, más preferiblemente más de 20%. Reivindicacion 5: El método de una o más de las reivindicaciones precedentes, caracterizado porque los al menos dos ingredientes con actividad farmacéutica se seleccionan del grupo que consiste en ingredientes activos apropiados para la inhalacion, preferiblemente analgésicos, agentes anti-anginales, antialergénicos, antibioticos, antiinfecciosos, antihistamínicos, antiinflamatorios, antitusivos broncodilatadores, drogas anticolinérgicas, hormonas, xantinas, vacunas, proteínas o péptidos terapéuticos y combinaciones de éstos, más preferiblemente albuterol, beclometasona, budesonida, carmoterol, ciclesonida, fenoterol, fluticasona, formoterol, indacaterol, ipratropio, mometasona, salbutamol, salmeterol, tiotropio y sales o solvatos farmacéuticamente aceptables de éstos. Reivindicacion 6: El método de una o más de las reivindicaciones precedentes, caracterizado porque los excipientes se seleccionan del grupo que consiste en los azucares y los sacáridos preferiblemente la lactosa con grado de inhalacion, preferiblemente el a monohidrato de lactosa en forma de lactosa cristalina, lactosa triturada o lactosa micronizada.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09153082A EP2221048A1 (en) | 2009-02-18 | 2009-02-18 | Pharmaceutical composition for inhalation |
Publications (1)
Publication Number | Publication Date |
---|---|
AR075516A1 true AR075516A1 (es) | 2011-04-06 |
Family
ID=40810348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100100474A AR075516A1 (es) | 2009-02-18 | 2010-02-18 | Composicion farmaceutica para inhalacion |
Country Status (29)
Country | Link |
---|---|
US (1) | US8840930B2 (es) |
EP (2) | EP2221048A1 (es) |
JP (1) | JP2012517987A (es) |
KR (1) | KR20110120283A (es) |
CN (1) | CN102325523B (es) |
AR (1) | AR075516A1 (es) |
AU (1) | AU2010215490B2 (es) |
BR (1) | BRPI1008598A2 (es) |
CA (1) | CA2749231C (es) |
CY (1) | CY1119216T1 (es) |
DK (1) | DK2398464T3 (es) |
EA (1) | EA021123B1 (es) |
ES (1) | ES2607210T3 (es) |
HK (1) | HK1160034A1 (es) |
HR (1) | HRP20170014T1 (es) |
HU (1) | HUE030618T2 (es) |
IL (1) | IL214036A (es) |
LT (1) | LT2398464T (es) |
MX (1) | MX341250B (es) |
NZ (1) | NZ594026A (es) |
PL (1) | PL2398464T3 (es) |
PT (1) | PT2398464T (es) |
RS (1) | RS55527B1 (es) |
RU (1) | RU2493833C2 (es) |
SI (1) | SI2398464T1 (es) |
SM (1) | SMT201700095B (es) |
UA (1) | UA102138C2 (es) |
WO (1) | WO2010094731A2 (es) |
ZA (1) | ZA201105532B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
BR112013008974A2 (pt) | 2010-10-12 | 2023-12-19 | Cipla Ltd | Composição farmacêutica, processo para fabricar uma composição farmacêutica e uso de uma composição farmacêutica |
CN102451173B (zh) * | 2010-10-22 | 2015-02-18 | 山东新时代药业有限公司 | 噻托溴铵胶囊型吸入粉雾剂 |
TR201105367A2 (tr) * | 2011-06-02 | 2012-12-21 | Bi̇lgi̇ç Mahmut | Akış özellikleri geliştirilmiş bir kuru toz formülasyonu. |
TR201205852A2 (tr) * | 2011-06-02 | 2012-12-21 | Bi̇lgi̇ç Mahmut | Geliştirilmiş yeni kuru toz formülasyonu. |
US20150202321A1 (en) * | 2012-08-14 | 2015-07-23 | Newgen Biopharma Corp. | Compositions comprising chitosan-drug conjugates and methods of making and using the same |
CN103860525B (zh) * | 2012-12-11 | 2016-04-06 | 天津药物研究院 | 一种含有效成分安立生坦的胶囊型吸入粉雾剂及其制备工艺 |
KR20160030086A (ko) * | 2013-04-29 | 2016-03-16 | 사노피 에스에이 | 흡입식 약학적 조성물 및 그를 포함하는 흡입기 장치 |
EP2991625A1 (en) * | 2013-04-29 | 2016-03-09 | Sanofi SA | Inhalable pharmaceutical compositions and the inhaler devices containing them |
EP2815739B1 (en) * | 2013-06-17 | 2019-08-28 | Arven Ilac Sanayi Ve Ticaret A.S. | Inhalation composition filling method |
UA118861C2 (uk) | 2013-12-06 | 2019-03-25 | Оріон Корпорейшн | Спосіб отримання сухих порошкових композицій для інгаляцій |
CN103784449A (zh) * | 2014-02-18 | 2014-05-14 | 青岛市城阳区人民医院 | 一种包含茚达特罗和噻托溴铵的药物组合产品 |
PT109030B (pt) * | 2015-12-15 | 2019-09-25 | Hovione Farmaciência, S.A. | Preparação de partículas inaláveis de zafirlucaste |
CN107095875B (zh) * | 2016-02-23 | 2022-03-18 | 天津金耀集团有限公司 | 一种昔奈酸沙美特罗丙酸氟替卡松复方粉吸入剂组合物 |
CN108066329B (zh) * | 2016-11-11 | 2021-11-16 | 江苏恒瑞医药股份有限公司 | 一种吸入用氟替卡松或其衍生物的微粒的制备方法 |
CN107823193B (zh) * | 2017-11-16 | 2021-02-05 | 广州迈达康医药科技有限公司 | 一种阿地溴铵吸入型粉雾剂及其制备方法 |
PT3833964T (pt) | 2018-08-07 | 2023-08-17 | Norton Waterford Ltd | Aplicação de espetroscopia de raman para o fabrico de pós de inalação |
CA3189493A1 (en) | 2020-08-14 | 2022-02-17 | Brian Paul O'NEILL | An inhalable formulation of fluticasone propionate and albuterol sulfate |
WO2022146255A1 (en) * | 2020-12-31 | 2022-07-07 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | A process for the preparation of dry powder compositions for inhalation |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4140689B4 (de) * | 1991-12-10 | 2007-11-22 | Boehringer Ingelheim Kg | Inhalationspulver und Verfahren zu ihrer Herstellung |
ATE239447T1 (de) | 1997-09-29 | 2003-05-15 | Inhale Therapeutic Syst | In verneblern verwendbare, stabilisierte zubereitungen |
ITMI991582A1 (it) * | 1999-07-16 | 2001-01-16 | Chiesi Farma Spa | Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala |
DE19947235A1 (de) * | 1999-09-30 | 2001-04-05 | Asta Medica Ag | Neue Kombination von Loteprednol und beta¶2¶-Adrenorezeptor-Agonisten |
GB0012260D0 (en) * | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel composition |
WO2003024396A2 (en) | 2001-09-17 | 2003-03-27 | Glaxo Group Limited | Dry powder medicament formulations |
EP1494652A1 (en) * | 2002-04-12 | 2005-01-12 | Campina Nederland Holding B.V. | Excipient for use in dry powder inhalation preparations |
GB2395900A (en) * | 2002-12-04 | 2004-06-09 | Elan Drug Delivery Ltd | Therapeutic composition for respiratory delivery |
US20040152720A1 (en) * | 2002-12-20 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powdered medicaments containing a tiotropium salt and salmeterol xinafoate |
JP5524442B2 (ja) * | 2004-02-06 | 2014-06-18 | メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 呼吸器疾患の治療のための、抗コリン作用薬及びβ−模倣薬の新規併用薬 |
CN101175480A (zh) | 2005-03-16 | 2008-05-07 | 伊兰制药国际有限公司 | 纳米微粒白三烯受体拮抗剂/皮质类固醇制剂 |
GB0714134D0 (en) * | 2007-07-19 | 2007-08-29 | Norton Healthcare Ltd | Dry-powder medicament |
-
2009
- 2009-02-18 EP EP09153082A patent/EP2221048A1/en not_active Withdrawn
-
2010
- 2010-02-18 EA EA201190108A patent/EA021123B1/ru not_active IP Right Cessation
- 2010-02-18 AR ARP100100474A patent/AR075516A1/es unknown
- 2010-02-18 JP JP2011549610A patent/JP2012517987A/ja active Pending
- 2010-02-18 ES ES10711610.5T patent/ES2607210T3/es active Active
- 2010-02-18 DK DK10711610.5T patent/DK2398464T3/en active
- 2010-02-18 UA UAA201110089A patent/UA102138C2/uk unknown
- 2010-02-18 PT PT107116105T patent/PT2398464T/pt unknown
- 2010-02-18 NZ NZ594026A patent/NZ594026A/xx not_active IP Right Cessation
- 2010-02-18 EP EP10711610.5A patent/EP2398464B1/en active Active
- 2010-02-18 BR BRPI1008598A patent/BRPI1008598A2/pt not_active Application Discontinuation
- 2010-02-18 US US13/202,081 patent/US8840930B2/en not_active Expired - Fee Related
- 2010-02-18 KR KR1020117018559A patent/KR20110120283A/ko not_active Application Discontinuation
- 2010-02-18 MX MX2011008659A patent/MX341250B/es active IP Right Grant
- 2010-02-18 RU RU2011133322/15A patent/RU2493833C2/ru not_active IP Right Cessation
- 2010-02-18 RS RS20161193A patent/RS55527B1/sr unknown
- 2010-02-18 CN CN201080007956.4A patent/CN102325523B/zh not_active Expired - Fee Related
- 2010-02-18 CA CA2749231A patent/CA2749231C/en not_active Expired - Fee Related
- 2010-02-18 PL PL10711610T patent/PL2398464T3/pl unknown
- 2010-02-18 LT LTEP10711610.5T patent/LT2398464T/lt unknown
- 2010-02-18 AU AU2010215490A patent/AU2010215490B2/en not_active Ceased
- 2010-02-18 SI SI201031353A patent/SI2398464T1/sl unknown
- 2010-02-18 WO PCT/EP2010/052026 patent/WO2010094731A2/en active Application Filing
- 2010-02-18 HU HUE10711610A patent/HUE030618T2/en unknown
-
2011
- 2011-07-12 IL IL214036A patent/IL214036A/en not_active IP Right Cessation
- 2011-07-27 ZA ZA2011/05532A patent/ZA201105532B/en unknown
-
2012
- 2012-01-26 HK HK12100760.4A patent/HK1160034A1/zh not_active IP Right Cessation
-
2016
- 2016-12-23 CY CY20161101340T patent/CY1119216T1/el unknown
-
2017
- 2017-01-05 HR HRP20170014TT patent/HRP20170014T1/hr unknown
- 2017-02-10 SM SM201700095T patent/SMT201700095B/it unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR075516A1 (es) | Composicion farmaceutica para inhalacion | |
ES2687751T3 (es) | Tratamiento de enfermedades respiratorias | |
ES2270806T3 (es) | Combinaciones de formoterol y de una sal de tiotropio. | |
AR101593A2 (es) | Formulación superfina de formoterol | |
JP2012517987A5 (ja) | 吸入用の医薬組成物のfpd特性を設定する方法 | |
BRPI0508170A (pt) | formulações farmacêuticas para inaladores de pó seco, que compreendem um ingrediente ativo de potência de baixa dosagem | |
AR067639A1 (es) | Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente | |
BR0308274A (pt) | Formulação de formoterol superfino | |
FI3500241T3 (fi) | Yhdistelmähoito copd:lle | |
ES2775606T3 (es) | Furoato de fluticasona en el tratamiento de la EPOC | |
JP2013531056A5 (es) | ||
FI2265257T4 (fi) | Aklidiniumia käsittävä inhalaatiokoostumus kroonisen keuhkoahtaumataudin hoitamiseksi | |
CN103501781A (zh) | 吡咯糖用于治疗心动过速的用途 | |
NZ627837A (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
JP2019528316A5 (es) | ||
JP2012522767A (ja) | ステロイド性[3,2−c]ピラゾール誘導体および第二の薬学的活性化合物を含む医薬組成物 | |
KR20170003601A (ko) | Copd의 치료를 위한 티오트로피움 브로마이드, 포르모테롤 및 부데소니드의 조합 | |
JP2015519356A5 (es) | ||
AR040450A1 (es) | Formulacion superfina de salmeterol | |
WO2005044187A3 (en) | Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same | |
UY28589A1 (es) | Nuevas sales de tiotropio, procedimientos para su preparación , así como formulaciones medicamentosas que las contienen | |
WO2005044186A3 (en) | Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same | |
Ahmadiafshar et al. | Efficacy and safety of inhaled and intranasal corticosteroids | |
RU2020112519A (ru) | Ингалятор и сетка для ингалятора | |
PAVIA et al. | Preliminary data from phase II studies with Respimat, a propellant-free soft mist inhaler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |